# Pulmonary Disease, Chronic Obstructive FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/pulmonary-disease-chronic-obstructive

> 16 upcoming FDA catalysts in pulmonary Disease, Chronic Obstructive: brenipatide (LLY) on May 2028 (primary completion); brenipatide (LLY) on May to Aug 2028 (topline data readout); depemokimab (GSK) on Dec 2028 to Mar 2029 (topline data readout); depemokimab (GSK) on Dec 2028 to Mar 2029 (topline data readout); and 12 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2028 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07759245 (A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07759245)) |
| May to Aug 2028 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07759245 (A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07759245)) |
| Dec 2028 to Mar 2029 | [Depemokimab topline data readout](https://sec-api.dev/pdufa/depemokimab) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT06959095 (Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-13 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06959095)) |
| Dec 2028 to Mar 2029 | [Depemokimab topline data readout](https://sec-api.dev/pdufa/depemokimab) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT06961214 (Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-13 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06961214)) |
| December 2028 | [Depemokimab primary completion](https://sec-api.dev/pdufa/depemokimab) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT06959095 (Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-13 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06959095)) |
| December 2028 | [Depemokimab primary completion](https://sec-api.dev/pdufa/depemokimab) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT06961214 (Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-13 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06961214)) |
| Mar to Jun 2029 | [GSK3862995B topline data readout](https://sec-api.dev/pdufa/gsk3862995b) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07915791 (A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-03-16 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07915791)) |
| March 2029 | [GSK3862995B primary completion](https://sec-api.dev/pdufa/gsk3862995b) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07915791 (A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-03-16 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07915791)) |
| Apr to Jul 2029 | [Depemokimab topline data readout](https://sec-api.dev/pdufa/depemokimab) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07177339 (eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07177339)) |
| Apr to Jul 2029 | [Ohtuvayre (ensifentrine) topline data readout](https://sec-api.dev/pdufa/ensifentrine) | MRK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07874815 (Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-29 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07874815)) |
| April 2029 | [Ohtuvayre (ensifentrine) primary completion](https://sec-api.dev/pdufa/ensifentrine) | MRK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07874815 (Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-29 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07874815)) |
| April 2029 | [Depemokimab primary completion](https://sec-api.dev/pdufa/depemokimab) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07177339 (eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07177339)) |
| Jul to Oct 2029 | [GSK5784283 topline data readout](https://sec-api.dev/pdufa/gsk5784283) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07780656 (A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-20 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07780656)) |
| Jul to Oct 2029 | [GSK5784283 topline data readout](https://sec-api.dev/pdufa/gsk5784283) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07780669 (A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-20 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07780669)) |
| July 2029 | [GSK5784283 primary completion](https://sec-api.dev/pdufa/gsk5784283) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07780656 (A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-20 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07780656)) |
| July 2029 | [GSK5784283 primary completion](https://sec-api.dev/pdufa/gsk5784283) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07780669 (A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-20 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07780669)) |

## Drugs

- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [Depemokimab](https://sec-api.dev/pdufa/depemokimab) (GSK)
- [GSK3862995B](https://sec-api.dev/pdufa/gsk3862995b) (GSK)
- [Ohtuvayre (ensifentrine)](https://sec-api.dev/pdufa/ensifentrine) (MRK)
- [GSK5784283](https://sec-api.dev/pdufa/gsk5784283) (GSK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/pulmonary-disease-chronic-obstructive.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Pulmonary Disease, Chronic Obstructive FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/pulmonary-disease-chronic-obstructive

```bibtex
@misc{secapidev_indications_pulmonary_disease_chronic_obstructive_20261116,
  title        = {Pulmonary Disease, Chronic Obstructive FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/pulmonary-disease-chronic-obstructive}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_pulmonary_disease_chronic_obstructive_20261116","title":"Pulmonary Disease, Chronic Obstructive FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/pulmonary-disease-chronic-obstructive","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
